Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL
By MwanashaMerrill, MDPembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. Phase 2 Pembro (MK-3475) study is designed to look at using PD-1 blockade after transplant to see if that would improve the outcomes of these patients. It was open label, it was non randomized, and we ended up enrolling about 21 patients. For this study, we for the study to be interesting. Based on our statistical study results, we needed 13 out of the 21 patient. Pembrolizumab is now being researched as a potential treatment for more than 30 different types of cancer, both as a monotherapy and in combination with other drugs. It is anticipated that by the end of 2014, the program will grow to include more than 24 clinical trials spanning 30 unique types of tumors, recruiting over 6,000 patients at approximately 300 clinical trial sites across the globe. Arm C is a phase II, multicenter study of the anti-PD-1 monoclonal antibody pembrolizumab administered following ASCT for multiple subtypes of lymphoma. PTCL NOS was the most common histology (52%) and 90% of patients were in complete metabolic response prior to ASCT. The toxicity evaluation (n = 21) comprised all patients who received at least one dosage of the study's therapy. Mwanasha Hamuza Merrill, MD is a medical oncology clinical Fellow in Medicine at the Dana-Farber Cancer Institute. She holds a Doctor of internal medicine degree focusing on Non-Lymphoma Hodgkin's while participating in clinical studies. Merrill: Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma.
Watch and Share the Video Here: https://oncologytube.com/v/41705
Read and Share the Article Here: https://oncologytube.com/v/41706
Listen and Share the Audio Podcast Here: https://oncologytube.com/v/41707
